Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Crispr Therapeutics Ag (NQ: CRSP )

50.84 +1.53 (+3.10%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 27, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Crispr Therapeutics Ag

< Previous 1 2
...
19 20 21 22 23 24 25 26 27
...
30 31 Next >
Cathie Wood Has Bet Big On These 10 Stocks; Here's How They're Performing
Here's how Ark Invest's top holdings have performed in 2022. 
Via Investor's Business Daily
2 Stocks Near 52-Week Highs That Could Climb Higher
This pair of stocks are bucking the trend and they could climb even higher. 
Via The Motley Fool
Cathie Wood Is Selling This High-Flying Stock. Here's Why You Should Buy It Instead
The ARK Invest founder might regret trimming her position in this biotech stock. 
Via The Motley Fool
What 5 Analyst Ratings Have To Say About CRISPR Therapeutics
Via Benzinga
How to Trade the High-Growth Biotech Sector in the Midst of a Bear Market
Biotech is an exciting and emerging space that’s attracted increasing investor interest in recent years. 
Via Benzinga
Why Shares of CRISPR Therapeutics Dropped 19.9% in October
Several factors weighed on the gene-editing biotech stocks last month. 
Via The Motley Fool
Where CRISPR Therapeutics Stands With Analysts
CRISPR Therapeutics (NASDAQ:CRSP) has observed the following analyst ratings within the last quarter: 
Via Benzinga
Where Will Editas Medicine Be in 1 Year?
The company could continue lagging the market for a while. 
Via The Motley Fool
2 Growth Stocks That Could Double in 2023
Both are lagging the market this year. 
Via The Motley Fool
Crispr Therapeutics Stock: Bull vs. Bear
Crispr shares have fallen about 20% so far this year. 
Via The Motley Fool
5 Top Stocks to Buy Before 2023
These stocks have what it takes to win over time. 
Via The Motley Fool
Vertex Pharmaceuticals: Buy at the High?
Vertex is submitting a potential blockbuster to regulators this month. 
Via The Motley Fool
Want $1 Million in Retirement? Invest $100,000 in These 3 Stocks and Wait a Decade
These top stocks could be wise additions to a well-rounded investment portfolio. 
Via The Motley Fool
3 Top Healthcare Stocks Defying the Bear Market
These healthcare companies haven't been slowed by macroeconomic conditions. 
Via The Motley Fool
$100 Invested In This Stock 5 Years Ago Would Be Worth $300 Today
CRISPR Therapeutics (NASDAQ:CRSP) has outperformed the market over the past 5 years by 15.41% on an annualized basis producing an average annual return of 23.37%. Currently, CRISPR Therapeutics has a... 
Via Benzinga
3 Healthcare Stocks That Could Go Parabolic
These beaten-down stocks are ready for a rebound. 
Via The Motley Fool
Got $1,000? 2 Smart Stocks to Consider Buying Right Now
Don't overlook these major healthcare names on your next stock-buying spree. 
Via The Motley Fool
2 Biotech Stocks That Could Make You Richer
Both drugmakers are pretty close to their 52-week highs, but that shouldn't stop investors. 
Via The Motley Fool
3 Top Healthcare Stocks to Buy for November
Catalysts lie ahead for these promising stocks. 
Via The Motley Fool
What 8 Analyst Ratings Have To Say About CRISPR Therapeutics
Within the last quarter, CRISPR Therapeutics (NASDAQ:CRSP) has observed the following analyst ratings: 
Via Benzinga
Expert Ratings for CRISPR Therapeutics
Over the past 3 months, 8 analysts have published their opinion on CRISPR Therapeutics (NASDAQ:CRSP) stock. These analysts are typically employed by large Wall Street banks and tasked with... 
Via Benzinga
Better Buy: CRISPR Therapeutics vs. Bluebird Bio
These two companies have performed almost equally poorly on the stock market in the past year. 
Via The Motley Fool
2 Monster Stocks to Buy Without Any Hesitation
These stocks are crushing the bear market. 
Via The Motley Fool
Here's How Much $100 Invested In CRISPR Therapeutics 5 Years Ago Would Be Worth Today
CRISPR Therapeutics (NASDAQ:CRSP) has outperformed the market over the past 5 years by 13.48% on an annualized basis producing an average annual return of 21.37%. Currently, CRISPR Therapeutics has a... 
Via Benzinga
S&P 500 Biotech Giant Vertex Leads 5 Stocks Showing Strength
Vertex and LNG play Cheniere Energy are setting up bullishly. 
Via Investor's Business Daily
The Top 5 Stocks Cathie Wood Bought and Sold This Week
Cathie Wood's flagship ETF, the ARK Innovation ETF, hit a five-year and 52-week low this week, casting doubts on the investment manager. 
Via InvestorPlace
2 Budding Growth Stocks That Could Turn $1,000 Into $10,000 in 8 Years
They're both using unique and highly efficient approaches to developing and deploying their medicines. 
Via The Motley Fool
CRISPR Stocks: Will Concerns Over Risk Inhibit Gene-Editing Cures?
Despite enthusiasm in some camps, the risk of potential cures clouds market projections. 
Via Investor's Business Daily
2 Under-the-Radar Biotech Stocks to Buy in 2022
These two drugmakers are growing in prominence. 
Via The Motley Fool
3 Cathie Wood Stocks to Buy and Hold for 10 Years
The risks are formidable, but the chances of a massive gain are too much to pass up. 
Via The Motley Fool
< Previous 1 2
...
19 20 21 22 23 24 25 26 27
...
30 31 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.